NASDAQ
GEHC
Last Price
US $73.79
KEY FIGURES
MKT CAP
$33.3B
EPS
TTM
$3.51
EPS Growth (1Y)
4.84%
PEG
TTM
33.49x
P/E
TTM
21.00x
P/S
TTM
1.65x
YIELD
0.19%
GROWTH (5Y CAGR)
Profit margin
Current Ratio
Capital Returns
15.16%
Return on equity
ROIC: 8.15%
Valuation History
21.2X
Price to Earnings
EV/EBITDA: 11.9X
Cash flow
Profit margin
Revenue
3.74%
EBITDA
2.13%
Cash flow
1.07%
Cash Flow (DCF)
Fair Value
Market $73.79
-61.49%
Default assumptions
EBITDA Multiple
Fair Value
Market $73.79
-37.61%
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.
Valuation
Financial
Performance
Cash flow to debt coverage
GE HealthCare Technologies Inc. cash flow to debt ratio of 19.87% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.
Free cash flow growth
GE HealthCare Technologies Inc.'s free cash flow has decreased 2.84% from $1.55B last year to $1.51B, signaling decreasing performance
Debt-to-equity ratio
GE HealthCare Technologies Inc.'s debt to equity ratio is 0.92, which means that the company's assets are unhealthy financed, signaling financial risk.
Debt-to-equity trend
GE HealthCare Technologies Inc.'s debt has decreased relative to shareholder equity from 1.11 last year to 0.92 today, signaling strengthened financials
Net debt to EBITDA
GE HealthCare Technologies Inc. has a net debt to EBITDA ratio of 1.45x, which is below the 3.00x threshold, indicating healthy leverage and financial stability
Interest coverage
GE HealthCare Technologies Inc.'s interest coverage ratio of 5.90 indicates that earnings with good margin can cover interest payments on company debt
Profit margin growth
GE HealthCare Technologies Inc.'s profit margin has decreased (22.37%) in the last year from 10.13% to 7.86%, signaling decreasing performance
Current ratio
GE HealthCare Technologies Inc.'s short-term assets of $10.70B exceed its short-term liabilities of $9.11B
Return on assets
GE HealthCare Technologies Inc.'s return on assets of 4.27% is lower than the 5.00% threshold, indicating inefficient asset utilization
Return on equity
GE HealthCare Technologies Inc.'s return on equity of 15.16%, is higher than 15.00%, indicating good performance
Earnings quality
GE HealthCare Technologies Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Earnings stability
GE HealthCare Technologies Inc. has insufficient public price history to evaluate earnings stability.
Positive free cash flow
GE HealthCare Technologies Inc. has positive free cash flow, indicating the company generates cash after capital expenditures
Free cash flow yield
GE HealthCare Technologies Inc. has a free cash flow yield of 4.57%, which is above the 2.00% threshold, indicating strong cash generation relative to market value
Earnings growth
GE HealthCare Technologies Inc.'s yearly earnings has increased 4.57% since last year from $1.99B to $2.08B, signaling increasing performance
Revenue growth
GE HealthCare Technologies Inc.'s yearly revenue has decreased 0.37% since last year from $19.67B to $19.60B, signaling decreasing performance
Return on invested capital
ROIC 8.15% (Source: FMP key-metrics). In the 5–10% partial-credit band. Score: 1 of 2. This band sits within the typical US weighted-average cost of capital range. Methodology choice can change the conclusion: under FMP's invested-capital definition the company is at or near its cost of capital; under narrower operating-capital definitions the same company may score higher. Invested capital here includes equity, non-current liabilities, and short-term debt. Cash is not subtracted. See methodology.
3-year revenue CAGR
GE HealthCare Technologies Inc.'s 3-year revenue CAGR of 3.99% is positive, indicating growing revenue over the past 3 years
Revenue consistency
GE HealthCare Technologies Inc. has insufficient public price history to evaluate revenue consistency.
Return on equity consistency
GE HealthCare Technologies Inc. has insufficient public price history to evaluate ROE consistency.
Cash Flow Valuation (DCF)
GE HealthCare Technologies Inc. is overvalued relative to its fair value price of 28.42 based on Discounted Cash Flow model
Earnings yield (TTM)
GE HealthCare Technologies Inc. has an earnings yield of 4.82%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings
EBITDA Valuation
GE HealthCare Technologies Inc. is overvalued relative to its fair value price of 46.04 based on EBITDA multiple model
EV/EBITDA (FY)
GE HealthCare Technologies Inc. has an EV/EBITDA ratio of 10.16x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings
PEG ratio (TTM/FY)
GE HealthCare Technologies Inc. has a PEG-ratio over 1 which is considered overvalued
Price-to-book ratio (FY)
GE HealthCare Technologies Inc. has a price-to-book ratio of 3.01x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value
Price-to-sales ratio (TTM)
GE HealthCare Technologies Inc. has a price-to-sales ratio of 1.63x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue